BioSpace News Archive

A rise in the incidence of various chronic diseases such as obesity, diabetes, and various autoimmune diseases is likely to foster growth of the global acupuncture needles market over the timeframe of analysis, from 2019 to 2029.

Transparency Market Research has published a new report titled, ‘Small bone and joint orthopedic devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

GemVax & KAEL a clinical stage company developing novel immunotherapies based on telomerase modification announced the decision to apply for an expanded access IND for its lead candidate GV1001 to include additional investigational groups in Alzheimer’s, a disease the WHO estimates to affect 24 million people worldwide, in its clinical development program.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce multiple introductory purchase orders for OxC-betaTM Livestock with new clients in Mexico.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the company plans to present at the following conferences.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that three poster presentations will feature the company’s new silicone hydrogel daily disposable contact lens, Bausch + Lomb INFUSE™, during the virtual American Academy of Optometry Annual Meeting.

Imbio, a leading provider of artificial intelligence solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases.

Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced the grant of options to purchase 39,000 shares of its common stock to three new employees and the grant of 22,500 restricted stock units to two of the three new employees.

Independent Data Monitoring Committee (IDMC) conducted a pre-planned interim analysis of the Company’s Phase III Comfort™ trial of Piclidenoson for the treatment of psoriasis and recommended to continue with this psoriasis study A separate IDMC for the pre-planned interim analysis of the Acrobat™ Rheumatoid Arthritis (RA) Phase III study recommended not to continue this study. The Company plans to undertake a detailed analysis of the data of the

NN, Inc., a diversified industrial company, announced that it has successfully completed the sale of its Life Sciences division to affiliates of American Securities LLC for the purpose of being combined with MW Industries, one of its portfolio companies.